ライフサイエンスコーパス: aripiprazole

1 nd-generation antipsychotics (risperidone or aripiprazole).

2 or some, but not all, outcomes (minocycline, aripiprazole).

3 treatment with risperidone, paliperidone, or aripiprazole.

4 :1:1 ratio) to placebo or 10 or 30 mg/day of aripiprazole.

5 speridone and for PANSS negative scores with aripiprazole.

6 l effects of two D2R ligands, quinpirole and aripiprazole.

7 d risk with continued risperidone use versus aripiprazole.

8 behavioral phenotypes and are responsive to aripiprazole.

9 l magnetic stimulation (rTMS), ketamine, and aripiprazole.

10 d for paliperidone (3-month formulation) and aripiprazole.

11 opion; or augmentation with an antipsychotic-aripiprazole.

12 and Drug Administration (FDA)-approved drug aripiprazole.

13 eeks of treatment with either risperidone or aripiprazole.

14 the atypical APDs olanzapine (1.0 mg/kg) or aripiprazole (0.3 mg/kg) significantly potentiated the e

15 cute haloperidol treatment (0.6 mg/kg i.p.), aripiprazole (1 mg/kg, i.p.) reversed the depolarization

16 modification of the scaffold represented by aripiprazole (1), we discovered UNC9975 (2), UNC0006 (3)

17 [1.01-1.17]), with the possible exception of aripiprazole (1.36 [1.14-1.63]).

18 rm 1= amisulpride 400 mg/day, N = 24; Arm 2= aripiprazole 10 mg/day, N = 24) for one week, followed b

19 h positive symptoms, 537 mg/day and 85.8 mg; aripiprazole, 11.5 mg/day and 1.8 mg; aripiprazole LAI (

20 Aripiprazole (20 and 30 mg/d) and risperidone (6 mg/d) w

21 tients in an acute manic or mixed episode to aripiprazole, 30 mg/day (reduced to 15 mg/day if needed

22 d to 5-HT or bound to the antipsychotic drug aripiprazole; 5-HT(1D) bound to 5-HT; and 5-HT(1E) in co

23 tematic review (total n=949, amisulpride=20, aripiprazole=8, chlorpromazine=13, haloperidol=316, intr

24 all timepoints was significantly higher for aripiprazole (97.1%) than for quetiapine-ER (89.2%; p=0.

25 by extensively exploring multiple regions of aripiprazole, a balanced D2R agonist.

26 authors compared the efficacy and safety of aripiprazole, a novel antipsychotic, to placebo for trea

27 ating deficits and rearing are attenuated by aripiprazole, a partial agonist at dopamine type II rece

28 ripiprazole), sedation (quetiapine, OFC, and aripiprazole), abnormal metabolic laboratory results (qu

29 We found that administration of aripiprazole acutely or after 1 or 7 days of withdrawal

30 HOMA-IR group difference at week 12 favoured aripiprazole (adjusted mean log-transformed group differ

31 sychotics (aHR=0.46, 95% CI=0.34-0.62), oral aripiprazole (aHR=0.68, 95% CI=0.56-0.82), and oral olan

32 Aripiprazole also removes haloperidol-induced depolariza

33 Aripiprazole, an AAP considered metabolically sparing, i

34 Eleven patients were treated with aripiprazole and 13 patients were treated with risperido

35 Remission occurred in 40 (43%) who received aripiprazole and 26 (29%) who received placebo.

36 axine hydrochloride monotherapy, 91 received aripiprazole and 90 received placebo.

37 tein-selective partial agonism was found for aripiprazole and cariprazine.

38 omanic symptoms (for which augmentation with aripiprazole and combination with bupropion were more ef

39 ability of the combination of olanzapine or aripiprazole and DVX to enhance ACh efflux in the HIP or

40 Novel dopamine receptor antagonists aripiprazole and ecopipam have shown potential efficacy

41 ne as well as two other antipsychotic drugs, aripiprazole and haloperidol, resulted in a strong reduc

42 Based on these findings, olanzapine, aripiprazole and paliperidone are the best choices for t

43 Our estimates support use of aripiprazole and paliperidone as first-line therapies fo

44 d with 50% reduced odds of remission in both aripiprazole and placebo arms.

45 nts did not differ significantly between the aripiprazole and placebo groups.

46 here were no significant differences between aripiprazole and placebo in mean change from baseline in

47 ail Making Test scaled score of less than 7, aripiprazole and placebo were equally efficacious (OR, 0

48 ealthy males received either single doses of aripiprazole and risperidone (n=28), amisulpride and lor

49 k 1 for PANSS total and positive scores with aripiprazole and risperidone and for PANSS negative scor

50 Aripiprazole and risperidone groups showed a similar low

51 The 95% CIs for olanzapine versus aripiprazole and risperidone included the possibility of

52 ural hybridization of the antipsychotic drug aripiprazole and the heterocyclic catecholamine surrogat

53 n may respond favorably to augmentation with aripiprazole and thus may help to personalize treatment.

54 anzapine), fatigue, sedation, akathisia (for aripiprazole), and extrapyramidal symptoms.

55 nd the D2-selective ligands methylspiperone, aripiprazole, and its congener OPC4392 [7-[3-(4-(2,3-dim

56 Like methylspiperone, aripiprazole, and OPC4392, the two D4-selective 1,4-DAPs

57 bes systematic evaluation of the efficacy of aripiprazole, and parent training combined with risperid

58 nd clinical ADR profiles of methylphenidate, aripiprazole, and risperidone, and of kinase drugs targe

59 for molecular imprinting of an electroactive aripiprazole antipsychotic drug were herein designed and

60 edications, including the DA partial agonist aripiprazole (APZ), have been inconsistent, suggesting t

61 n antipsychotics (for example, clozapine and aripiprazole) are effective in some patient populations.

62 Some antipsychotic drugs, such as aripiprazole, are less efficacious in internalizing D2R

63 Aripiprazole (ARI) exposure, independent of genetic muta

64 ich the two drugs used were specified (i.e., aripiprazole, aripiprazole once monthly, aripiprazole+la

65 Initiating aripiprazole as antipsychotic monotherapy rather than ol

66 gene, identified the atypical antipsychotic aripiprazole as one of the hits.

67 als, while augmentation with higher doses of aripiprazole (as well as with high doses of all other an

68 Compared with the placebo, aripiprazole, asenapine, carbamazepine, cariprazine, hal

69 Compared with the placebo, aripiprazole, asenapine, carbamazepine, cariprazine, hal

70 t of mania symptoms (N = 61, n = 15466), and aripiprazole, asenapine, carbamazepine, cariprazine, hal

71 otypical atypical APD, clozapine, as well as aripiprazole, asenapine, iloperidone, lurasidone, olanza

72 Antipsychotic agents, such as quetiapine, aripiprazole, asenapine, lurasidone, and cariprazine, ar

73 cal antipsychotic drugs, such as quetiapine, aripiprazole, asenapine, lurasidone, and cariprazine.

74 Akathisia was more common with aripiprazole at week 2 (observed in 34 [60%] of 57 patie

75 ; or augment with an atypical antipsychotic, aripiprazole (augment-aripiprazole group, n = 505) for 1

76 eline set shifting moderated the efficacy of aripiprazole augmentation (odds ratio [OR], 1.66 [95% CI

77 ror (se)) = -17.39 (1.3) (p = 0.015) but not aripiprazole augmentation (score change (se) = -14.9 (1.

78 ram daily; nonresponders at 8 weeks received aripiprazole augmentation for 8 additional weeks.

79 nd Canada to test the efficacy and safety of aripiprazole augmentation for adults aged older than 60

80 up to a 12-week randomized clinical trial of aripiprazole augmentation for first-line treatment-resis

81 using clozapine, indicates that medium-dose aripiprazole augmentation of clozapine treatment is asso

82 oral olanzapine, quetiapine, risperidone and aripiprazole augmentation of clozapine treatment on the

83 n-group differences were not significant for aripiprazole augmentation versus bupropion augmentation

84 (180 to <330 mg/day) clozapine, medium-dose aripiprazole augmentation was the only treatment more ef

85 patients were enrolled; 211 were assigned to aripiprazole augmentation, 206 to bupropion augmentation

86 n of existing antidepressant medication with aripiprazole, augmentation with bupropion, or a switch f

87 The difference between the aripiprazole-augmentation group and the switch-to-buprop

88 mission occurred in 28.9% of patients in the aripiprazole-augmentation group, 28.2% in the bupropion-

89 Only aripiprazole augmentations were associated with a decrea

90 placebo, but confidence was poor, with only aripiprazole (both LAI and OS) showing "moderate" confid

91 Administration for treatment of depression (aripiprazole, brexpiprazole, cariprazine, extended-relea

92 clozapine exhibiting the worst profiles and aripiprazole, brexpiprazole, cariprazine, lurasidone, an

93 Some second-generation antipsychotics (e.g., aripiprazole, brexpiprazole, cariprazine, quetiapine XR)

94 dding a second treatment (adding quetiapine, aripiprazole, buspirone alpha2delta ligand agents) is re

95 Mean prolactin levels decreased with aripiprazole but significantly increased 5-fold with ris

96 Risperidone and aripiprazole can improve irritability and aggression (st

97 sterol biosynthesis, including haloperidol, aripiprazole, cariprazine, fluoxetine, trazodone and ami

98 psychotics including haloperidol, clozapine, aripiprazole, chlorpromazine, quetiapine, olanzapine, ri

99 ountries was medium-dose (9 to <16.5 mg/day) aripiprazole combined with high-dose (>=330 mg/day) cloz

100 creased right putamen volume estimates after aripiprazole compared to placebo.

101 The chemosensor was successfully applied for aripiprazole determination in human plasma.

102 At the end of the study, both aripiprazole doses showed statistically significant diff

103 a lower remission rate but did not moderate aripiprazole efficacy; each standard deviation greater a

104 Conversely, the dopamine antagonist aripiprazole exacerbates sepsis mortality.

105 MIP-aripiprazole film-coated electrodes were used as extende

106 imated 12-month risks of discontinuation for aripiprazole, first-generation agents, olanzapine, palip

107 ns of LAIs, only haloperidol was inferior to aripiprazole, fluphenazine, and paliperidone.

108 acute efficacy, safety, and tolerability of aripiprazole for adolescents with schizophrenia.

109 There was an option to switch to aripiprazole for excessive adverse effects.

110 (valdecoxib for myocardial infarction (MI), aripiprazole for MI, and telithromycin for acute liver f

111 ect size and adverse effects associated with aripiprazole, further analysis including cost-effectiven

112 Response was greater for the augment-aripiprazole group (74.3%) than for either the switch gr

113 itch group [n = 124] vs 16.6% in the augment-aripiprazole group [n = 84]; and 22.5% in augment-buprop

114 A greater proportion of participants in the aripiprazole group achieved remission than did those in

115 e events occurring in more than 5% of either aripiprazole group and with a combined incidence at leas

116 The augment-aripiprazole group exceeded the switch group in remissio

117 Adverse effects more frequent in the augment-aripiprazole group included somnolence, akathisia, and w

118 tiapine-ER group vs 52 [91%] patients in the aripiprazole group), increased duration of sleep (47 [92

119 typical antipsychotic, aripiprazole (augment-aripiprazole group, n = 505) for 12 weeks (acute treatme

120 n group, and 28.9% (n = 146) for the augment-aripiprazole group.

121 Here we show that patients initiating aripiprazole had a similar five-year MACE risk as those

122 there was evidence that patients prescribed aripiprazole had better outcomes on other cardiometaboli

123 However, patients prescribed aripiprazole had better outcomes on some other cardiomet

124 Aripiprazole had significantly greater efficacy than pla

125 r prior hospitalisation, patients prescribed aripiprazole had similar rates of psychiatric hospitalis

126 Patients prescribed aripiprazole had similar total cholesterol levels after

127 In head-to-head comparisons, only LAI aripiprazole had superior acceptability to other LAIs (b

128 s were observed in the patients treated with aripiprazole, haloperidol lactate (CYP2D6 PM vs NM RoM,

129 We investigated the hypothesis that aripiprazole has a favourable cardiometabolic profile, b

130 gnosed with severe mental illness prescribed aripiprazole have similar total cholesterol 1 year after

131 or agonists (e.g., terguride, preclamol, and aripiprazole) have antagonist-like effects at normosensi

132 , oral risperidone (hazard ratio=1.15), oral aripiprazole (hazard ratio=1.14), oral ziprasidone (haza

133 y, for those predicted to survive, only oral aripiprazole (HR, 0.38 [95% CI, 0.20-0.69]) and risperid

134 s for eight second-generation antipsychotics-aripiprazole, iloperidone, olanzapine, paliperidone, que

135 ugmentation of existing antidepressants with aripiprazole improved well-being significantly more over

136 ] of 48, and 34 [72%] of 47 patients and for aripiprazole in 49 [89%] of 55, 52 [96%] of 54, and 44 [

137 eeks of treatment with either risperidone or aripiprazole in a double-blind randomized clinical trial

138 pine-extended release (quetiapine-ER) versus aripiprazole in children and adolescents with first-epis

139 d-to-head comparison of quetiapine-ER versus aripiprazole in early-onset psychosis showed no signific

140 T), and interpersonal therapy in depression; aripiprazole in mania; fluoxetine and group CBT in anxie

141 ed the efficacy, safety, and tolerability of aripiprazole in patients with acute exacerbation of schi

142 cardiometabolic safety and effectiveness of aripiprazole in the management of severe mental illness.

143 Aripiprazole increased longevity in a Drosophila model o

144 Aripiprazole increased PPI in low PPI gaters, whereas mo

145 mazine verus clozapine or haloperidol versus aripiprazole,increased incidence of the metabolic syndro

146 ed with density functional theory (DFT), and aripiprazole interactions with imprinted cavities were s

147 Aripiprazole is a dopamine D2 receptor partial agonist w

148 Aripiprazole is a dopamine partial agonist approved for

149 Aripiprazole is an antipsychotic drug characterized by p

150 We aimed to assess whether aripiprazole is associated with a higher probability of

151 a first-line antidepressant, the addition of aripiprazole is effective in achieving and sustaining re

152 Aripiprazole is effective, safe, and well tolerated for

153 The dopamine partial agonist aripiprazole is increasingly used to treat pathologies f

154 (AHR, 0.36 [95% CI, 0.31-0.42]), followed by aripiprazole LAI (AHR, 0.60 [95% CI, 0.57-0.63]), olanza

155 (AHR, 0.66; 95% CI, 0.51-0.86), followed by aripiprazole LAI (AHR, 0.77 [95% CI, 0.70-0.84]), olanza

156 .8 mg; aripiprazole, 11.5 mg/day and 1.8 mg; aripiprazole LAI (lauroxil), 463 mg every 4 weeks and 26

157 itude) amisulpride-oral (OS), olanzapine-OS, aripiprazole-LAI, olanzapine-LAI, aripiprazole-OS, palip

158 e., aripiprazole, aripiprazole once monthly, aripiprazole+lamotrigine, aripiprazole+valproate, asenap

159 Switching to aripiprazole led to improvement of non-HDL cholesterol l

160 Aripiprazole+LIT/VAL and quetiapine+LIT/VAL outperformed

161 ble analysis, clozapine (hazard ratio=0.43), aripiprazole long-acting injectable (LAI) (hazard ratio=

162 New prescriptions of aripiprazole (lower metabolic risk) increased during the

163 sychotic combination therapies (SGAs) (i.e., aripiprazole, lurasidone, olanzapine, quetiapine, and zi

164 Previously, we showed that aripiprazole may protect motivational function by preser

165 Aripiprazole (mean change (se) = -37.79 (2.9) (p = 0.003

166 The aripiprazole-mediated decrease in ATXN3 abundance may re

167 cated GTS patients, this was not the case in aripiprazole-medicated GTS patients.

168 stabilization of dopamine via intra-striatal aripiprazole microinjection suppresses the effects of LT

169 er consisting of patients who were receiving aripiprazole monotherapy, and to healthy subjects.

170 , and by 4.4 kg (95% CI, 3.7 to 5.2 kg) with aripiprazole (n = 41) compared with the minimal weight c

171 randomly assigned to quetiapine-ER (n=55) or aripiprazole (n=58).

172 did not remit and were randomly assigned to aripiprazole (n=91) or placebo (n=90).

173 We included 26,537 patients (aripiprazole, n = 3,573, olanzapine, n = 8,554, quetiapi

174 ignificant effects on remission, as follows: aripiprazole (odds ratio [OR], 2.01; 95% CI, 1.48-2.73),

175 dds ratio: 1.26, 95% CI: 1.14-1.39), but not aripiprazole (odds ratio: 1.19, 95% CI: 0.94-1.52) was a

176 eness of lamotrigine, topiramate, valproate, aripiprazole, olanzapine, and omega-3 fatty acid supplem

177 tions of paliperidone (3-month formulation), aripiprazole, olanzapine, and paliperidone (1-month form

178 ranging from 0.12 and 0.20 were observed for aripiprazole, olanzapine, and risperidone.

179 cally significant benefits were observed for aripiprazole, olanzapine, and risperidone.

180 d response to treatment (N = 56, n = 14503); aripiprazole, olanzapine, quetiapine, and risperidone ha

181 However, only aripiprazole, olanzapine, quetiapine, and risperidone ha

182 Treatment with aripiprazole, olanzapine, quetiapine, or risperidone for

183 ical), and for the most commonly used drugs (aripiprazole, olanzapine, quetiapine, risperidone, and h

184 ntry) of oral haloperidol and atypical APMs (aripiprazole, olanzapine, quetiapine, risperidone, etc).

185 14, 2012) identified 14 short-term trials of aripiprazole, olanzapine/fluoxetine combination (OFC), q

186 oronary disease, pain (small ES); quetiapine/aripiprazole/olanzapine induced WG (small to large ES).

187 To test the influence of aripiprazole on counterfactual learning, we administered

188 However, the effect of aripiprazole on more cognitive facets of human reinforce

189 bination of DVX, 50 mg/kg, and olanzapine or aripiprazole, on DA efflux in both the HIP and mPFC.

190 ugs used were specified (i.e., aripiprazole, aripiprazole once monthly, aripiprazole+lamotrigine, ari

191 -end-point changes were not significant with aripiprazole or in the untreated comparison group.

192 Aripiprazole or placebo tablets were started at 2 mg dai

193 mpare the effectiveness of augmentation with aripiprazole or repetitive transcranial magnetic stimula

194 e (OR, 1.61; 95% CI, 0.99-2.64; P = .06) and aripiprazole (OR, 1.58; 95% CI, 1.21-2.07; P = .001) but

195 icant effects on response rates, as follows: aripiprazole (OR, 2.07; 95% CI, 1.58-2.72; NNT, 7), OFC

196 hiatric disease, we administered olanzapine, aripiprazole, or placebo for 9 days to healthy subjects

197 zapine-OS, aripiprazole-LAI, olanzapine-LAI, aripiprazole-OS, paliperidone-OS, and ziprasidone-OS.

198 5 [5.46] for quetiapine-ER, -6.21 [5.42] for aripiprazole; p=0.98), but decreased over time in both g

199 in descending ranking order) zuclopenthixol, aripiprazole, paliperidone (3-month formulation), olanza

200 to 20 mg/d (n = 101) or 30 mg/d (n = 101) of aripiprazole, placebo (n = 103), or 6 mg/d of risperidon

201 the lowest risk was observed for medium-dose aripiprazole plus high-dose clozapine (aHR=0.70, 95% CI:

202 The structure of the aripiprazole pre-polymerization complex with functional

203 Our results suggest that whereas aripiprazole preserves direct learning of action-outcome

204 Aripiprazole produced statistically significant mean imp

205 of five mono-APDs: olanzapine, risperidone, aripiprazole, quetiapine, or amisulpride.

206 Therefore, aripiprazole rapidly reduced the hyperdopaminergic activ

207 It is unclear whether aripiprazole reduces dopamine neuron activity via inhibi

208 inistration of the high-affinity D2 agonist, aripiprazole, reduces not only functional downregulation

209 thisia was the most common adverse effect of aripiprazole (reported in 24 [26%] of 91 participants on

210 Aripiprazole represents a potentially promising therapeu

211 The potential signal for aripiprazole requires replication in other data before c

212 nd 0.2 kg for placebo and 10 mg and 30 mg of aripiprazole, respectively.

213 antidepressant treatment, augmentation with aripiprazole resulted in a statistically significant but

214 d with placebo, except for those assigned to aripiprazole (risk ratio [RR] 0.62, 95% credible interva

215 disorder for several marketed drugs (such as aripiprazole, risperidone and haloperidol).

216 in attention-deficit/hyperactivity disorder; aripiprazole, risperidone and several psychosocial inter

217 Aripiprazole, risperidone, and amisulpride increased P50

218 iapine with less akathisia than haloperidol, aripiprazole, risperidone, and olanzapine, but, again, e

219 ies focused on exploring four regions of the aripiprazole scaffold, which resulted in the discovery o

220 first G protein-biased D2R agonist from the aripiprazole scaffold.

221 several adverse events, including akathisia (aripiprazole), sedation (quetiapine, OFC, and aripiprazo

222 a] and change from preceding phase [mania]), aripiprazole separated from placebo by day 4.

223 ), quetiapine (SMD=0.25, 95% CI: 0.12-0.38), aripiprazole (SMD=0.16, 95% CI: 0.04-0.28) and risperido

224 ER (starting from 50 mg/day) or 20 mg/day of aripiprazole (starting from 2.5 mg/day).

225 e randomly assigned (1:1) to the addition of aripiprazole (target dose 10 mg [maximum 15 mg] daily) d

226 ompletion rate was significantly higher with aripiprazole than with placebo (42% versus 21%).

227 of remission were significantly higher with aripiprazole than with placebo (53% vs 28%; number neede

228 Compared with aripiprazole, the 12-month risk differences were -15.3%

229 n contrast to the weak agonistic behavior of aripiprazole, these ligands are capable of effectively m

230 s ranged from 1.9 (95%CI = [1.25; 2.91]) for aripiprazole to 12.86 (95%CI = [4.07; 40.63]) for ECT.

231 om olanzapine, quetiapine, or risperidone to aripiprazole to ameliorate metabolic risk factors for ca

232 ranged from OR = 1.57 95%CI [0.97, 2.56] for aripiprazole to OR = 7.56 95%CI [3.16, 18.08] for halope

233 The impact of acute and repeated aripiprazole treatment was examined in the methylazoxyme

234 zole once monthly, aripiprazole+lamotrigine, aripiprazole+valproate, asenapine, carbamazepine, lamotr

235 All active treatments, other than aripiprazole+valproate, carbamazepine, lamotrigine, and

236 Aripiprazole+valproate, lamotrigine, lamotrigine+valproa

237 search Datalink data, we emulated a trial of aripiprazole versus olanzapine, quetiapine, and risperid

238 ational emulation of a head-to-head trial of aripiprazole versus olanzapine, quetiapine, and risperid

239 wer among patients initiating and continuing aripiprazole versus risperidone (0.58, 95% CI, 0.39-0.84

240 (reported in 24 [26%] of 91 participants on aripiprazole vs 11 [12%] of 90 on placebo).

241 Compared with placebo, aripiprazole was also associated with more Parkinsonism

242 ere similar between groups, but switching to aripiprazole was associated with a higher rate of treatm

243 Aripiprazole was generally well tolerated.

244 In mixed age groups, in bipolar disorder aripiprazole was metabolically neutral; in depression, S

245 : age >=65 years (for whom augmentation with aripiprazole was more effective than switch to bupropion

246 t changes in body weight versus placebo, and aripiprazole was not associated with elevated serum prol

247 Both 10- and 30-mg/day doses of aripiprazole were superior to placebo in the acute treat

248 ial agonists at DA D2 receptors (D2Rs), like aripiprazole, were developed to simultaneously target bo

249 iated with more metabolic adverse events and aripiprazole with more initial akathisia and, unexpected

250 xtended gates for selective determination of aripiprazole with the extended-gate field-effect transis

251 Pretreatment of olanzapine or aripiprazole with the selective serotonin 5-HT(1A) antag

252 cation (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, asenapine, iloperidone, or pa